上半年关店241家、营利双降，一心堂的“跑马圈地”不灵了？

Core Viewpoint - YXTT Pharmaceutical Group Co., Ltd. (referred to as "YXTT") has reported a decline in performance for the first half of 2025, with revenue of 8.914 billion yuan, down 4.20% year-on-year, and a net profit of 250 million yuan, down 11.44% year-on-year, indicating challenges in its aggressive expansion strategy [1][2][3] Group 1: Financial Performance - In 2023, YXTT experienced its first revenue decline since its listing, with revenue of 17.38 billion yuan, down 0.29% year-on-year, and a net profit of 549 million yuan, down 45.60% year-on-year [1] - For 2024, YXTT's revenue increased to 18.0 billion yuan, up 3.6% year-on-year, but net profit fell to 114 million yuan, down 79.2% year-on-year [2] - In Q1 2025, YXTT reported revenue of 4.767 billion yuan, down 6.53% year-on-year, and a net profit of 160 million yuan, down 33.83% year-on-year [2] Group 2: Expansion Strategy - YXTT's aggressive "land grab" expansion model has led to increased operational costs, with new store openings contributing to rising expenses such as rent, decoration, and labor [2][3] - The company opened 2,867 new stores from 2020 to 2024, with 203 new stores opened and 241 closed in the first half of 2025, maintaining a total of 11,372 stores [3] Group 3: Regulatory Challenges - YXTT faced scrutiny from the National Medical Insurance Administration due to issues such as drug substitution and improper billing practices, resulting in the return of over 10 million yuan to the medical insurance fund [4][5] - Starting April 1, 2025, new regulations will require electronic prescriptions for dual-channel pharmacies, complicating operational processes and potentially impacting sales of prescription drugs [6] Group 4: Online Business Development - YXTT is actively developing its online business, achieving 727 million yuan in new retail sales in the first half of 2025, with O2O sales accounting for 81.02% [7] - The company aims to leverage big data and AI to enhance consumer health demand forecasting and explore cross-border e-commerce opportunities [7] Group 5: Industry Context - The retail pharmacy market is experiencing intense competition, with 35% of stores showing positive growth and 31% experiencing slight declines in early 2025 [8] - The industry is shifting from a focus on selling drugs to providing health services, necessitating a reevaluation of growth strategies in light of regulatory changes and market dynamics [8]